News

June 26, 2019

Report Identifies Proteins That Drive Spread in Castration-resistant PC

News

Inhibiting the protein BRD4 can stop the migration of castration-resistant prostate cancer cells, regardless of the mechanism causing resistance to treatment, new research has shown. This suggests that BRD4 might ... Read more

June 24, 2019

FDA OKs Phase 2 Trial of Ampligen Combo as Pre-surgery PC Treatment

News

The U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2 clinical trial testing Hemispherx Biopharma‘s Ampligen (rintatolimod), in combination with aspirin or aspirin plus Intron ... Read more

June 20, 2019

Investigational AMG 212 Shows Anti-cancer Activity in Advanced mCRPC in Phase 1 Trial

News

Amgen’s investigational therapy AMG 212 (pasotuxizumab) is safe, and showing therapeutic activity against metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1 clinical trial, data show. This is the first ... Read more

June 19, 2019

FDA Grants Arvinas’ ARV-110 Fast Track Designation for mCRPC

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Arvinas‘ lead protein degrader ARV-110 to treat patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has ... Read more

June 17, 2019June 17, 2019

Most Prostate Cancer Patients on Active Surveillance Don’t Follow Monitoring Guidelines, Study Shows

News

Most prostate cancer patients who choose to undergo active surveillance instead of treatment are not receiving the appropriate disease monitoring, bringing into question whether or not this is a safe ... Read more

June 13, 2019June 13, 2019

Study Shows How Prostate Cancer Cells Mimic Bone When They Metastasize

News

Prostate cancer cells can activate genes associated with bone formation and mimic bone cells’ behavior, allowing them to spread into bones. Those findings by by Duke University researchers, have revealed ... Read more

June 12, 2019

Darolutamide/ADT Combo Delays Disease Worsening in Some PC, Phase 3 Trial Shows

News

Darolutamide in combination with androgen deprivation therapy (ADT) delays disease worsening in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and stabilizes their quality of life without increasing the incidence of ... Read more

June 6, 2019

Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows

News

Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard of care, according to early findings of a large ... Read more

June 5, 2019

Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives

News

Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, ... Read more

June 3, 2019

American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer

News

Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to study ... Read more